INTRODUCTION
Newer technologies to detect jaundice and bilirubinemia have increasing clinical import as health care practice changes in the US with expectations of a demedicalized birthing practice, an earlier discharge with home-based care and a demand for noninvasive, safe, as well as precise, monitoring services. Neonatal jaundice, the commonest of clinical signs, and hyperbilirubinemia are the most frequently evaluated conditions and the most frequent of causes for hospital readmission after birthing. They also carry the potential but rare risk of neurologic devastation: kernicterus. 1 -3 As demonstrated a long time ago by Davidson et al. in 1941, 4 visual assessment of jaundice is a useful clinical technique but even under the best of conditions is relatively imprecise. Since 1941, several investigators scrutinized the clinical application of the visual assessment of jaundice and its cephalo-caudal progression and have been unable to demonstrate its clinical reliability as a means to either gauge intensity or predict subsequent hyperbilirubinemia. 5 -7 This is especially so in darker skinned babies in whom even as a screening tool, it can be dangerously misleading. Actual determination of bilirubin is the only option and this measurement needs to be precise and in the context of postnatal age in hours as well as percentile based. The measured level of neonatal bilirubinemia is due to the net balance between bilirubin production and its elimination. Technologies are now available to correlate the level of intravascular bilirubin production to exhaled carbon monoxide production (ETCO). However, assessment of bilirubin elimination (and that of the entero-hepatic circulation) is still dependent on assessment of clinical, epidemiological, and racial risk factors alone.
In this paper, we review the applications of present clinical technologies that determine the bilirubin load and its dynamic changes with postnatal age. The ability of these technologies to predict or prevent severe hyperbilirubinemia and differentiate between the factors contributing to excessive load have been reviewed in the context of predischarge and postdischarge bilirubin management of all newborns.
REVIEW OF CLINICAL JAUNDICE TECHNOLOGIES
Technologies to Measure Jaundice Visual assessment of clinical jaundice is influenced by the vagaries of color discrimination and visual sensitivity. Recognition of the time of appearance of clinical jaundice coupled with estimation of its cephalo-caudal rate of progression in comparison to concurrent TSB values has not proved to be an accurate predictor of severity or subsequent excessive hyperbilirubinemia. This is especially so in babies with varying degrees of skin pigmentation or in any infant evaluated in a room with low lighting by an inexperienced or overwhelmed professional. Table 1 provides the clinical applications to assess jaundice as well as methods to standardize its assessment.
Technologies to Measure Bilirubin Measurement of total serum bilirubin TSB measurement (Table 2) in term and near-term newborns, concurrent to the routine predischarge metabolic screening, when plotted on the hour-specific bilirubin nomogram, is preferred to a day-specific value and is a powerful and a significant vector. 8 It defines a series of populations at varying risk for subsequent excessive hyperbilirubinemia. Its predictive accuracy and significance as a powerful vector is shown in Figure 1 . Clinical significance of this data is not only identification of a high-risk population, which needs close monitoring, but also of a low-risk population. The latter may then be followed less intensively, which allows for efficient targeting of services as well as cost. The role of TSB as a predictive vector has now been validated by several other studies. 9, 10 Value -based hyperbilirubinemia. Clinicians and investigators have used diverse definitions of significant, severe, and excessive hyperbilirubinemia. From a historical perspective, a TSB value >20 mg/dl (340 mol/l) has been associated with a significantly increased risk of kernicterus in newborns with hemolytic diseases. An extrapolation of this value to infants, as an index for treatment in infants without hemolytic disease, was termed ''vigintiphobia'' 11 and so aggressive management in apparently healthy babies was questioned. Newman Rate of TSB rise -based hyperbilirubinemia. Investigators studying hemolytic disease of the newborn recognized a rate of rise in TSB >0.5 mg/dl per hour ( >8.6 mol/l per hour) as an ominous sign and a basis for prompt aggressive intervention. Maisels 13 has recommended that a rate of rise >5 mg/dl per day should be source of concern. The AAP guidelines suggest that a rate of TSB rise >0.25 mg/dl per hour (or, 6 mg/dl per day) should be viewed with concern in well babies and an indication for investigation and monitoring. 1 Percentile -based hyperbilirubinemia. The hour-specific bilirubin nomogram provides an easy way to locate a TSB value on a percentile-based frequency chart that defines risk tract for subsequent hyperbilirubinemia of increasing or decreasing severity. Statistically TSB values >95th percentile track on the hour-specific bilirubin nomogram represent an extraordinary segment of the well-baby population ( Figure 1 ) that has severe or significant hyperbilirubinemia. Because bilirubin elimination usually remains below bilirubin production during the first 72 hours after birth, an hourbased assessment of the net balance is shown by the ensuing changes in the percentile-based risk tract (''jumping of tracks'') or by maintenance of the original risk tract. Predischarge measurements of either TSB or TcB have been shown to be relatively accurate and useful predictors of subsequent postdischarge severe hyperbilirubinemia. 14 
Measurement of transcutaneous bilirubin (TcB)
Use of multiwavelength spectral reflectance to measure the optical density of cutaneous bilirubin multiracial populations.
The BiliCheck device (SpectRx; Norcross, GA) is a new transcutaneous bilirubin measuring instrument that uses the entire spectrum of visible light (380 to 760 nm) reflected from the skin. White light is transmitted into the skin of newborn (forehead or the sternum), and the reflected light is collected for analysis. The mathematical isolation of the light absorption of certain interfering factors (melanin pigment, chromophores, hemoglobin, and dermal thickness) allows the absorption of light by bilirubin in the capillary beds and the subcutaneous tissue to be isolated for spectral subtraction. Thus, theoretically, this will allow for unbiased measurement of bilirubin independent of race, ethnicity, gestational age and weight of the baby. This has been shown and accurate correlation to TSB measured by the HPLC technique has been demonstrated ( Figure 2 ). The intradevice and interdevice accuracy and precision of this device exceeds by far the performance of the standard clinical laboratory techniques. 14, 15 This technology differs from the Minolta JM-2 bilimeter, which now provides a direct TSB measure and is accurate in babies who are light skinned but has limited accuracy in babies with increased skin pigmentation. 16 However, because of the dynamics of bilirubin kinetics between the vascular space and the subcutaneous tissue (effect of rate of rise in bilirubin, affinity, and bilirubin binding to tissues) and the confounding effects of increasing concentrations on transmittance and reflectance measurements, the correlation of TcB to TSB should be viewed with caution when TcB values are >13 mg/dl. Measurements of TcB in a predischarge well-baby population may also be used as a predictive vector provided values >13 mg/dl are corroborated by TSB measurements.
Technologies to Measure Bilirubin Production (Table 3) (1) Measurement of exhaled carbon monoxide: Breakdown of the heme molecule results in an equimolar production of carbon monoxide. The measurement of CO in the exhaled breath has been shown to be an effective and an accurate index of bilirubin production 17 ( Table 3 ). The accuracy and precision for the measurement of carbon monoxide should be such that the sensitivity ±1 ppb of CO and the speed for measurement is <1 minute resolution and measure an ETCO value >3 /l. Moreover, the detector should be able to accurately differentiate between CO and hydrogen. The CO-Stat End Tidal Breath Analyzer (Natus, Palo Alto, CA) with a single disposable nasal sampler has been effectively used to analyze the breath in term and near-term infants for corrected to ambient carbon monoxide (ETCOc). The nasal sampler continuously draws air by sidestream sampling of nasal air at up to 60 ml/min. 18 The maximal level of exhaled carbon dioxide determines the sampling point at which ETCO level is determined and then corrected for the presampled value of ambient CO and provides a measure of ETCOc. The device achieves an accuracy of ±0.3 ppm for respiratory rates between 10 and 60 breaths per minute. The measurements are reproducible and have minimal coefficient of variance. 19 In a recent multinational study, Stevenson et al. 20 have explored the role for exhaled carbon monoxide (ETCOc), as a noninvasive measure of bilirubin production and as a vector of subsequent hyperbilirubinemia ( >75th percentile track). Babies with increased bilirubin production were defined by ETCOc values above the mean measured for those who did not develop hyperbilirubinemia. The combination of TSB ( >75th percentile track for age in hours) and ETCOc (more than the population mean) measured at 30±6 hours age yielded a positive predictive value of 6.4% and a negative predictive value of 99.0%. Stevenson et al. recommend that predischarge measurement of TSB may provide assistance in predicting and managing subsequent hyperbilirubinemia and note that the additional measurement of ETCOc may provide insight into the processes that contribute to hyperbilirubinemia but does not materially improve the predictive ability of an hour-specific TSB value alone. 20 The value of ETCOc Figure 2 . Correlation of TcB measurement, using the BiliCheck device (SpectRx ), to TSB measurement, as assayed by HPLC technique.
14 Figure 1 . Hour -specific bilirubin nomogram with the predictive ability of the predischarge bilirubin value for subsequent severe hyperbilirubinemia, > 95th percentile tract. 8 
Bhutani and Johnson
Prediction of Hyperbilirubinemia in Newborns before 30±6 hours age is more crucial as a potential screening and diagnostic vector for early-onset hyperbilirubinemia (predominantly related to either intravascular or extravascular hemolysis).
In clinical settings where routine blood typing of babies is not done and there are no routine means to screen or exclude neonatal hemolytic disorders, a system-based screening for hemolysis using ETCOc measurements has potential value and needs further study.
(2) Measurement of carboxyhemoglobin has been used to document the presence of hemolysis; however, it has not been validated for clinical applications and limited by being an invasive test. 21 
Technologies to Assess Bilirubin Load
The level of neonatal bilirubinemia is due to the net balance between bilirubin production and its elimination. As described above, technologies are now available to correlate the level of intravascular bilirubin production to exhaled carbon monoxide production (ETCOc) measured at 30±6 hours. In the presence of bruising and other reasons for extravascular hemorrhages, the measurement of ETCO has a potential value and needs further study. However, assessment of bilirubin elimination (and that of the entero-hepatic circulation) is dependent on assessment of clinical, epidemiological, and racial risk factors. 22 Decreased uridine-diphosphate glucoronyl-transferase activity as seen in Gilbert's syndrome that, depending on ethnicity, is associated with several different mutations in the promoter region of the UGTIAI gene that encodes this enzyme has been implicated in the diminished elimination of bilirubin. An association of both G6PD deficiency and a missense mutation of UGTIAI A (TA)/TAA are seen in some ethnic populations) can lead to severe hyperbilirubinemia. 23 -25 The magnitude of bilirubin load at one time can be estimated on the basis of an hour-specific percentile-based TSB/TcB value. These provide ''static'' assessment of bilirubinemia, which may be further characterized by the presence of clinical risk factors or measurement of bilirubin production (by ETCOc). The paradigm that influence and impact on the magnitude of the bilirubin load and how it may be further investigated is shown in Figure 3 .
With advancing postnatal age (in hours) the magnitude of bilirubin load may decrease in association with enhanced elimination or clearance of bilirubin or, it may increase because of increased bilirubin production from sequestered blood, infection, or exposure to hemolytic agents or entero-hepatic circulation and delayed clearance (see Figure 4) . These dynamic changes in the bilirubin load may be easily tracked by plotting serial age-specific TSB values on the bilirubin nomogram. Generally, over the first 3 to 4 days after birth, the bilirubin load increases but TSB generally remains in their original though individual percentile tract. However, there are exceptions defined by the statistical risk of ''jumping'' up (from one risk tract upwards to another), which increases with higher predischarge percentile-based TSB values (Figure 4) . Thus, the bilirubin nomogram can be used as a tool to track the dynamic changes in the bilirubin load; the components that lead to the increased load may be further investigated based on the paradigm depicted in Figure 4 .
CLINICAL APPLICATIONS
To facilitate the identification, evaluation and interventions for complications associated with hyperbilirubinemia, the AAP recommended consensus-based guidelines for the management of hyperbilirubinemia in 1994. These offer helpful, instructive approaches; however, with the current changes in health practices, areas that need closer attention are discussed below. In the subsequent section, we propose additional and optional strategies Figure 3 . Factors that impact on the static assessment of bilirubin load and as ascertained by a percentile -based hour -specific TSB / TcB measurement. ( Figure 5 ) to reduce the incidence and severity of excessive hyperbilirubinemia with the intent to prevent or minimize the occurrence of severe hyperbilirubinemia and kernicterus (as described in a brief case report; Figure 6 ).
Screening at or Soon After Birth
Hospital-based care of the healthy well baby is generally for about 48 hours age (as federally mandated) but subject to earlier discharge by mutual decision of the parent and the health care provider. As a public health policy for a multiracial population of diverse ethnicities, the visual assessment of jaundice in babies before hospital discharge (as recommended by the AAP) has significant limitations. This is confounded by the fact that routine screening for isoimmunization is not performed routinely unless the mother has Rh negative blood type and, sometimes, if she has blood type O. In addition, even though there are a substantial . Case report is illustrated of a newborn baby with a predischarge bilirubin assessment that was > 75th percentile tract ( thus, needing a follow-up for TSB within 24 hours, as shown in Figure 5 ). The baby was readmitted with ''dangerous'' hyperbilirubinemia after the mother kept her ''routine'' follow-up appointment 2 days after discharge. Upon readmission, the baby did not have overt signs of bilirubin encephalopathy; a two -volume exchange transfusion was done for an elevated value of unbound bilirubin ( UB) and a TSB value > 25 mg / dl. The baby is normal at follow-up.
Mediterranean, East Asian, African American, or other ethnicities at increased risk for G6PD deficiency, there is no mechanism for a rapid enough routine screening for this disorder. It is in these contexts that the universal predischarge bilirubin screening is strongly recommended.
Arranging for Post Birthing Discharge Follow-Up A postdischarge follow-up must not only ensure compliance by the family but also achieve, with significant medical certainty, that the rate of rise in TSB will not exceed 6 mg/dl per 24 hours. Numerous studies and reports have addressed the issues of difficulties in ensuring a postdischarge follow-up and the increasing frequencies of readmission following early discharge. These have been for excessive hyperbilirubinemia, dehydration, inadequate breast-feeding, intercurrent pathologies such as sepsis and exposure to hemolytic agents, and kernicterus. Ensuring a (reimbursed) follow-up visit, anticipating parental compliance, achieving medical certainty and evaluation by a credentialed pediatric professional while maintaining a kinder, gentler approach is indeed challenging.
PROPOSED SYSTEM-BASED APPROACH FOR PRE-AND POSTDISCHARGE MANAGEMENT OF NEONATAL JAUNDICE
Evidence and risk-based management of neonatal hyperbilirubinemia can and must be implemented in the US in a practical, timely, but rationale cautious way such that occurrence of kernicterus will soon again be at its irreducible minimum. This approach would envisage universal predischarge management including (1) vigilant observation and evaluation by both nursing and medical staff at the birthing site with prompt TSB measurement by nursery protocol before 24 hours age with the consideration of jaundice as a clinical vital sign; (2) development of noninvasive screening methodologies to identify babies at risk for early-onset hyperbilirubinemia and hemolysis (for increased bilirubin production in babies with earlyonset hyperbilirubinemia: bilirubin values >75th percentile track at age <60 hours); (3) predischarge measurement of total serum bilirubin at time of metabolic screen or by an accurate noninvasive transcutaneous measurement; and (4) further evaluation for hemolytic disorders such blood group incompatibilities, G6PD deficiency; (5) postdischarge follow-up, which is universal and characterized not only by the predischarge bilirubin risk assessment but also as assessment for other risk of changes in the bilirubin load secondary to factors such as bruising, near-term gestation, adequacy of breast-feeding, weight loss, and sepsis. These two approaches would help ensure a safe first week for the newborn. Lastly, any baby who does manifest a ''dangerous hyperbilirubinemia'' such as serum bilirubin value >25 mg/dl (427 mol/l) should be identified and entered into a database for ongoing recordkeeping and long-term follow-up such that an accurate incidence of this degree of hyperbilirubinemia can be ascertained and any evidence of bilirubin related neurotoxicity prospectively collected.
CONCLUSIONS
Neonatal jaundice is not only an outpatient problem but one that can have dangerous consequences before discharge. Furthermore, risk of subsequent hyperbilirubinemia can be reasonably and accurately predicted before the family is discharged from the close and continual medical observation. A system-based approach for bilirubin management, possible during hospitalization, and of predischarge and postdischarge parental education regarding adequacy of nutritional intake (especially breast milk) and significance of jaundice as a potentially serious condition, together with a mechanism to monitor for any occurrence of dangerous hyperbilirubinemia, can be accomplished by judicious and costeffective use of the newer jaundice technologies. Although the cost effectiveness of these technologies is evaluated by research and institutional scrutiny, we as pediatricians must consider and provide the protective mantle of care that will ensure not only a gentler but a more judicious approach to jaundice in the era of early hospital discharge and managed care.
